Literature DB >> 24111878

Co-morbidities and hyperinflation are independent risk factors of all-cause mortality in very severe COPD.

Stephan Budweiser1, Martina Harlacher, Michael Pfeifer, Rudolf A Jörres.   

Abstract

BACKGROUND: COPD is a multi-component disease that is not sufficiently reflected by FEV1 alone. We studied in patients with very severe COPD, which dimensions of the disease, including co-morbidities, dominate prognosis.
METHODS: In patients with FEV1 < 30% predicted, anthropometric, laboratory, spirometric and body plethysmographic data, smoking status, alcohol consumption, the level of dyspnoea and exercise performance were assessed. Co-morbidities were categorized by the Charlson-index and the COPD-specific co-morbidity test (COTE). The prognostic value of multiple dimensions was explored using uni- and multivariate survival analyses regarding death from any or respiratory cause.
RESULTS: Among 209 patients included (58/151 female/male; FEV1 25.0 (22.0-26.9)%predicted), arterial hypertension (54.1%), hyperlipidemia (38.3%) and diabetes (19.6%) were most common, 57.9% showing a COTE-index of ≥ 1 point. During follow-up (28 (14-45) months), 121 patients had died, mostly (56.2%) due to respiratory causes. Age, BMI, the ratio of residual volume to total lung capacity (RV/TLC), co-morbidities in terms of the COTE- and Charlson-index, but not FEV1, were significantly associated with all-cause and respiratory mortality. The association of the median values of the Charlson- (HR 1.911 [95%-CI 1.338-2.730]) and COTE-index (HR 1.852 [95%-CI 1.297-2.644], p < 0.001 each) with mortality was similar and stronger when combined with age. In multivariate analyses, only RV/TLC and co-morbidities were independent risk factors of all-cause mortality (p < 0.05 each).
CONCLUSION: In very severe COPD, resting hyperinflation and co-morbidities provide the major prognostic information, whereas the association of the recently introduced COTE-index with mortality was similar to that of the established Charlson-index and even stronger when including age.

Entities:  

Keywords:  co-morbidity score; long-term survival; prognostic factors; residual volume

Mesh:

Year:  2013        PMID: 24111878     DOI: 10.3109/15412555.2013.836174

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  21 in total

1.  Integrating COPD into Patient-Centered Hospital Readmissions Reduction Programs.

Authors:  Jerry A Krishnan; Hélène A Gussin; Valentin Prieto-Centurion; Jamie L Sullivan; Farhan Zaidi; Byron M Thomashow
Journal:  Chronic Obstr Pulm Dis       Date:  2015

2.  BMI moderates the association between adverse childhood experiences and COPD.

Authors:  Megan R Westmore; Priyanjali Chakraborty; LaTisha A Thomas; Lacey Jenkins; Faheem Ohri; Philip Baiden
Journal:  J Psychosom Res       Date:  2022-07-16       Impact factor: 4.620

3.  Sex-specific associations of comorbidome and pulmorbidome with mortality in chronic obstructive pulmonary disease: results from COSYCONET.

Authors:  Franziska C Trudzinski; Rudolf A Jörres; Peter Alter; Julia Walter; Henrik Watz; Andrea Koch; Matthias John; Marek Lommatzsch; Claus F Vogelmeier; Hans-Ulrich Kauczor; Tobias Welte; Jürgen Behr; Amanda Tufman; Robert Bals; Felix J F Herth; Kathrin Kahnert
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

Review 4.  Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and Management.

Authors:  Nirupama Putcha; M Bradley Drummond; Robert A Wise; Nadia N Hansel
Journal:  Semin Respir Crit Care Med       Date:  2015-08-03       Impact factor: 3.119

Review 5.  Pulmonary function testing in COPD: looking beyond the curtain of FEV1.

Authors:  Sotirios Kakavas; Ourania S Kotsiou; Fotis Perlikos; Maria Mermiri; Georgios Mavrovounis; Konstantinos Gourgoulianis; Ioannis Pantazopoulos
Journal:  NPJ Prim Care Respir Med       Date:  2021-05-07       Impact factor: 2.871

6.  Clinical impact of long-term change in air trapping on pulmonary function and computed tomography parameters in chronic obstructive pulmonary disease.

Authors:  Jeong Uk Lim; Jae Seung Lee; Ji-Hyun Lee; Sang-Do Lee; Yeon-Mok Oh; Chin Kook Rhee
Journal:  Korean J Intern Med       Date:  2020-11-25       Impact factor: 2.884

7.  The Prognostic Value of Residual Volume/Total Lung Capacity in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Tae Rim Shin; Yeon-Mok Oh; Joo Hun Park; Keu Sung Lee; Sunghee Oh; Dae Ryoung Kang; Seungsoo Sheen; Joon Beom Seo; Kwang Ha Yoo; Ji-Hyun Lee; Tae-Hyung Kim; Seong Yong Lim; Ho Il Yoon; Chin Kook Rhee; Kang-Hyeon Choe; Jae Seung Lee; Sang-Do Lee
Journal:  J Korean Med Sci       Date:  2015-09-12       Impact factor: 2.153

8.  The measurement of lung volumes using body plethysmography and helium dilution methods in COPD patients: a correlation and diagnosis analysis.

Authors:  Yongjiang Tang; Mingke Zhang; Yulin Feng; Binmiao Liang
Journal:  Sci Rep       Date:  2016-11-23       Impact factor: 4.379

9.  Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional UK Biobank study.

Authors:  Peter Hanlon; Barbara I Nicholl; Bhautesh Dinesh Jani; Ross McQueenie; Duncan Lee; Katie I Gallacher; Frances S Mair
Journal:  BMJ Open       Date:  2018-01-14       Impact factor: 2.692

10.  Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD.

Authors:  Sally Singh; François Maltais; Lee Tombs; William A Fahy; Mitra Vahdati-Bolouri; Nicholas Locantore; John H Riley
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.